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Abstract
Background: Advances in molecular diagnostics have implicated newly-discovered respiratory viruses in the pathogenesis
of pneumonia. We aimed to determine the prevalence and clinical characteristics of human bocavirus (hBoV), human
rhinovirus (hRV), polyomavirus-WU (WUPyV) and –KI (KIPyV) and human coronaviruses (CoV)-OC43, -NL63, -HKU1 and -229E
among children hospitalized with lower respiratory tract infections (LRTI).
Methods: Multiplex real-time reverse-transcriptase polymerase chain reaction was undertaken on archived nasopharyngeal
aspirates from HIV-infected and –uninfected children (,2 years age) hospitalized for LRTI, who had been previously
investigated for respiratory syncytial virus, human metapneumovirus, parainfluenza I–III, adenovirus and influenza A/B.
Results: At least one of these viruses were identified in 274 (53.0%) of 517 and in 509 (54.0%) of 943 LRTI-episodes in HIV-
infected and -uninfected children, respectively. Human rhinovirus was the most prevalent in HIV-infected (31.7%) and –
uninfected children (32.0%), followed by CoV-OC43 (12.2%) and hBoV (9.5%) in HIV-infected; and by hBoV (13.3%) and
WUPyV (11.9%) in HIV-uninfected children. Polyomavirus-KI (8.9% vs. 4.8%; p = 0.002) and CoV-OC43 (12.2% vs. 3.6%; p,
0.001) were more prevalent in HIV-infected than –uninfected children. Combined with previously-tested viruses, respiratory
viruses were identified in 60.9% of HIV-infected and 78.3% of HIV-uninfected children. The newly tested viruses were
detected at high frequency in association with other respiratory viruses, including previously-investigated viruses (22.8% in
HIV-infected and 28.5% in HIV–uninfected children).
Conclusions: We established that combined with previously-investigated viruses, at least one respiratory virus was
identified in the majority of HIV-infected and HIV-uninfected children hospitalized for LRTI. The high frequency of viral co-
infections illustrates the complexities in attributing causality to specific viruses in the aetiology of LRTI and may indicate a
synergetic role of viral co-infections in the pathogenesis of childhood LRTI.
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Introduction
Pneumonia is a leading cause of mortality in children under 5
years age worldwide, including in HIV-infected children [1–3].
The aetiology of childhood pneumonia may include infection with
bacteria and/or respiratory viruses. Although respiratory viruses
are more frequently identified than bacteria in children with
pneumonia, this may be biased by lack of availability of sensitive
and specific tests for diagnosing bacterial causes of pneumonia [4].
Furthermore, respiratory viral infections may heighten the
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susceptibility to developing a super-imposed bacterial infection
resulting in severe pneumonia [5,6]. Traditionally, respiratory
viruses that have been associated with lower respiratory tract
infections (LRTI) include respiratory syncytial virus (RSV),
parainfluenza viruses I–III (PIV I–III), influenza viruses A/B
and adenovirus. Two human coronaviruses (CoV), OC43 (CoV-
OC43) and 229E (CoV-229E) were initially identified as causes of
upper respiratory tract infections (URTI) in the 1960s using
classical culture methods [7,8]. More recently, advances in
molecular diagnostics have resulted in the discovery of other
respiratory viruses which have also been associated with LRTI.
Included among these are human metapneumovirus (hMPV) [9],
human bocavirus (hBoV) [10], human coronavirus NL63 (CoV-
NL63) [11] and HKU1 (CoV-HKU1) [12] and WU and KI
polyomaviruses (WUPyV, KIPyV) [13–15]. Also, human rhinovi-
rus (hRV), which was previously mainly associated with mild
URTI, has increasingly been implicated in having a role in the
pathogenesis of LRTI and asthma exacerbations [16,17].
Due to impaired humoral and cell-mediated immunity, HIV
infection in children has been described as a risk factor for severe
illness and mortality caused by respiratory-viral associated LRTI,
such as RSV, hMPV and influenza virus [18,19]. There are,
however, limited data on the role of other respiratory viruses,
including the more recently-discovered viruses which occur as
single or co-infecting pathogens in HIV-infected children hospi-
talized with LRTI, and of these studies, most have small sample
sizes [20–22].
The aim of this study was to identify the prevalence of hBoV,
hRV, WUPyV, KIPyV, CoV-OC43, CoV-NL63, CoV-HKU1
and CoV-229E among HIV-infected and -uninfected children
who were hospitalized for LRTI using real-time reverse transcrip-
tase–polymerase chain reaction (RT-PCR). The study-cohort had
been previously investigated for RSV, influenza A/B, PIV I-III
and adenovirus by immunofluorescence assay and hMPV by
nested-PCR as described [5,23].
Methods
Ethics Statement
The main 9-valent pneumococcal conjugated vaccine (PCV9)
efficacy trial and subsequent retrospective analysis of study
participants were approved by the Human Research Ethics
Committee (Medical) of the University of the Witwatersrand.
The main study did not have a clinical trials number since it was
undertaken prior to registration of clinical trials having been made
mandatory. Signed informed consent was obtained from the
parent/legal guardians of all the study participants as part of the
main trial. The Ethics Committee did not require additional
consent for this study.
Study population
This was a retrospective study of children who participated in a
phase III trial in South Africa which investigated the efficacy of a
PCV9 as described [5,24]. Briefly, 39836 children recruited from
March 1998 to October 2000 were randomized (1:1) to receive 3
doses of either PCV9 or placebo. Vaccination occurred at a mean
of 6.661.2 (6 standard deviation), 11.262.5, and 15.963.9 weeks
of age [24]. Hospital-based surveillance for all-cause hospitaliza-
tion was undertaken at Chris Hani-Baragwanath Hospital, the
only public hospital in the study community. Hospitalized children
had their signs and symptoms recorded and underwent HIV
testing according to the study protocol [24]. Nasopharyngeal
aspirates (NPA) were obtained for respiratory viral studies from
children hospitalized with LRTI [5], and archived from January
2000 onward. In the present study only NPA collected from 1st
February 2000 to 31st January 2002 from children less than 2 years
old were analysed. If a child had recurrent LRTI hospitalizations,
only NPA collected at least 28 days apart were included in the
analysis. Blood cultures were performed with the use of an
automated blood-culture system (BacT-Alert, Organon Teknika).
Viral testing
Total nucleic acids were extracted from archived NPA using a
NucliSENS easyMAG platform (bioMerieux), and eluted in a final
volume of 60 ml of elution buffer [25]. RNA was reverse
transcribed with High Capacity cDNA Reverse Transcriptase
(Invitrogen, Life Technologies) and primed with oligo-dT primers
(Invitrogen, Life Technologies). Real-time PCR was done in an
ABI 7500 RT-PCR system (Applied Biosystems, Life Technolo-
gies), reactions were performed in 20 ml using TaqMan Universal
PCR Master Mix (Applied Biosystems, Life Technologies) and the
primers and probes listed in Table S1.
Five duplex RT-PCR reactions, targeting the 8 respiratory
viruses, were developed. Internal controls (the human genes:
ribonucleoprotein and glyceraldehyde-3-phosphate dehydroge-
nase; or the spiked viruses: lambda and Newcastle Disease Virus)
were included to check the efficiency of the extraction step and to
detect the presence of PCR inhibitors. Positive controls were
included in each experiment.
Study-specific definitions
The clinical definitions used in this study are the same as
previously described [5]. Briefly, LRTI was defined as any episode
with clinical diagnosis of pneumonia or bronchiolitis done by a
study physician. Children with LRTI were categorized as having
clinical pneumonia if they had evidence of alveolar consolidation
on chest x-ray (CXR-AC) or if they fulfilled the clinical diagnosis
of LRTI without wheeze on chest auscultation but had rales and/
or bronchial breathing. Children were categorized as having
bronchiolitis in the presence of wheezing on chest auscultation and
in the absence of documented CXR-AC or bronchial breathing on
chest wall auscultation. A clinical diagnosis of WHO severe/very
severe pneumonia was made if the child had a cough ,14 days in
duration and lower chest wall in-drawing and/or any of the
following signs and symptoms of severe pneumonia: feeding
difficulties, convulsions, central cyanosis, or encephalopathy. The
previously developed respiratory index of severity in children
(RISC) score was used to compare disease severity between single
and multiple viral infections [26].
Statistical analysis
Demographic, clinical and laboratory characteristics at admis-
sion were compared between HIV-infected and –uninfected
children, chi-square or Fisher’s exact tests were used to compare
the distribution of categorical variables and mean or median of
continuous variables were compared by two-tailed Student t-test
or Mann-Whitney test, respectively. Viral prevalence was com-
pared between HIV groups and clinical and laboratory charac-
teristics were compared between episodes with single and multiple
viral detection using multivariate logistic regression models
adjusted for study intervention arm (i.e. whether received PCV9
or placebo), year of sampling, detection of a virus previously-tested
and age. The results are presented as adjusted odds ratios (aOR)
with 95% confidence intervals (95% CI) and p-values. A p-value,
0.05 was considered significant. Analyses were performed using
STATA version 11.0 (Statacorp, Texas, USA).
Respiratory Viruses in Hospitalized Children
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Results
Study population
During the follow-up period included in this analysis, there were
a total of 2147 hospitalizations for LRTI, including 2094 (97.5%)
in which NPA had been collected. Of the initial collected samples
69.7% were available for RT–PCR analysis. The same proportion
of samples were available for RT–PCR from PCV9-recipients
(69.2%) and placebo-recipients (70.2%; p= 0.621), from HIV-
infected (78.2% vs. 73.1%; p= 0.130) and HIV-uninfected
children (65.5% vs. 68.6%; p= 0.218); Table 1. A lower
proportion of samples was, however, available for RT-PCR
analysis (65.9% [1000/1518]) from the first period (February
2000–January 2001) compared to the second period (February
2001–January 2002) (79.9% [460/576]; p,0.001) of the study.
Children from whom NPA were available for RT–PCR testing
compared to those in whom samples were unavailable were older
(median age: 10 vs. 8 months; p,0.001), were 1.3-fold less likely to
have tested positive for one of the previously-tested respiratory
viruses (33.3% vs. 42.3%; p,0.001), had a higher prevalence of
cyanosis (11.4% vs. 8.1%; p= 0.025), higher evidence of CXR-AC
(26.6% vs. 22.1%; p= 0.041), higher C-reactive protein (CRP)
levels (median: 15 vs. 12 mg/l; p = 0.003) and higher procalcitonin
(PCT) concentration (median: 0.26 vs. 0.15 ng/ml; p = 0.006);
Table S2. There were no other demographic, clinical or
laboratory differences observed between the LRTI-episodes with
NPA available versus unavailable for RT-PCR.
A total of 517 NPA samples from HIV-infected children were
analysed by RT–PCR, including 45.0% from PCV9-recipients
and 55.0% from placebo-recipients. Among HIV-uninfected
children, 943 specimens were available for RT-PCR analysis,
including 49.5% from PCV9-recipients and 50.5% from placebo-
recipients. On admission HIV-infected children compared to
HIV-uninfected were younger (median age: 9 vs. 11 months; p,
0.001), more frequently presented with cyanosis (23.8% vs. 4.6%;
p,0.001), had lower mean oxygen saturation (89.8% vs. 92.2%;
p,0.001), had a higher median respiratory rate (54 vs. 48 breaths
per minute; p,0.001), were more likely to present as pneumonia
(88.8% vs. 49.6%; p,0.001) than bronchiolitis, had higher CRP
(18 vs. 14 mg/l; p = 0.007) and PCT levels (0.47 vs. 0.17 ng/ml;
p,0.001), had a longer hospital stay (4 vs. 1 median days; p,
0.001), had a higher case-fatality rate (17.8% vs. 0.95%; p,0.001)
and more frequently had bacteraemia (7.8% vs. 2.7; p,0.001);
Table 2.
Of the 1460 specimens analysed, all but 13 (1 from HIV-
infected and 12 from HIV-uninfected children) were previously
tested for hMPV by nested-PCR [23] and 1458 were tested by an
immunofluorescence assay for RSV, which if found negative, were
further tested for influenza A/B, PIV I–III and adenovirus as
described [5].
Prevalence of newly-tested respiratory viruses
Among HIV-infected children, the RT-PCR viral panel was
positive in 274 (53.0%) LRTI-episodes for at least one of the
newly-tested viruses; Table 3. The prevalence of any of the newly-
tested respiratory viruses was similar between PCV9- and placebo-
recipients in HIV-infected children, except for WUPyV (11.2% vs.
6.3%; p= 0.047, respectively) and hBoV (12.5% vs. 7.0%;
p= 0.034, respectively); Table S3. In HIV-infected children
hRV was the most frequently detected virus (31.7%) followed by
CoV-OC43 (12.2%), hBoV (9.5%), KIPyV (8.9%), WUPyV (8.5),
CoV-NL63 (1.7%) and CoV-HKU1 (1.4%); Table 3. The newly-
tested viruses were frequently identified as co-infecting viruses
among HIV-infected children, including 49.4% of LRTI-episodes
associated with hRV; Table 4. The most common viral co-
infections with hRV included KIPyV (14.6%), WUPyV (11.6%),
CoV-OC43 and hBoV (11.0%, each); Table 4. Among the 486
children on whom blood culture was done, bacteria were isolated
on 38 (7.8%) occasions, 20 (52.6%) of which were associated with
concomitant detection of one of the newly-tested viruses and 22
(57.9%) of any of the viruses.
In HIV-uninfected children at least one newly-tested virus was
detected in 509 (54.0%) LRTI-episodes, with hRV also being the
most common (32.0%), followed by hBoV (13.3%), WUPyV
(11.9%), KIPyV (4.8%), CoV-OC43 (3.6%), CoV-NL63 (2.6%),
CoV-HKU1 (1.6%) and CoV-229E (0.42%); Table 3. Comparing
HIV-uninfected PCV9 and placebo recipients, differences in the
prevalence of newly-tested viruses were evident for KIPyV (2.1%
vs. 7.4%; p,0.001), CoV-HKU1 (0.21% vs. 2.9%; p= 0.001),
CoV-OC43 (2.1% vs. 5.0%; p= 0.017) and hRV (36.2% vs.
27.9%; p= 0.007); Table S3. Of the 302 LRTI-episodes in which
hRV was identified, 51.3% had at least one other virus detected,
including 13.6% with RSV, 12.3% with WUPyV or hBoV and
2.0% (N=6) with both WUPyV and hBoV; Table 5. The
prevalence of bacteraemia in HIV-uninfected children among
those with blood culture results was 2.7% (N=24/881) of which
12 (50.0%) occurred in the presence of infection with one of the
newly-tested viruses and 15 (62.5%) in presence of any of the
studied viruses.
By multivariate analysis, adjusting for PCV-vaccination status,
period of collection and age, single infections with a newly-tested
virus were more frequent in HIV-infected (30.2%) than HIV-
uninfected children (25.5%) (adjusted odds ratio [aOR] 1.3;
p = 0.033); Table 3. Also, HIV-infected compared to HIV-
uninfected children had a higher prevalence of KIPyV (aOR
Table 1. Number of specimens analysed in the current study and total specimens collected.
Overall HIV-infected HIV-uninfected
Overall PCV9 Placebo p-value1Overall PCV9 Placebo p-value1Overall PCV9 Placebo p-value1
Visits according to study
criteria2
2147 1038 1109 712 310 402 1435 728 707
Nasopharyngeal aspirate done 2094 (97.5) 1010 (97.3) 1084 (97.7) 0.508 687 (96.5) 297 (95.8) 390 (97.0) 0.385 1407 (98.1) 713 (97.9) 694 (98.2) 0.762
Viral RT-PCR performed in this
study
1460 (69.7) 699 (69.2) 761 (70.2) 0.621 517 (75.3) 232 (78.2) 285 (73.1) 0.130 943 (67.0) 467 (65.5) 476 (68.6) 0.218
1: Chi-square test comparing 9-valent pneumococcal conjugated vaccine (PCV9) and placebo arms.
2: From the full database: patients ,2 years old, with diagnosis of lower respiratory tract infections, hospitalized between 1 February 2000 and 31 January 2002, only 1
visit per patient within 28 days.
doi:10.1371/journal.pone.0086448.t001
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Table 2. Demographic, clinical and laboratory features of children hospitalized for lower respiratory tract infection and in whom














Overall 10 (1–24) 9 (1–24) 11 (1–23) ,0.001Median age in months (range),
PCV9 10 (1–23) 8 (1–23) 11 (1–23) 0.018
Placebo 10 (1–24) 9 (1–24) 11(1–23) 0.009
p-value2 0.612 0.706 0.512
Overall 836 (57.3) 284 (54.9) 552 (58.5) 0.194Male3, N (%)
PCV9 423 (60.5) 137 (59.1) 286 (61.2) 0.577
Placebo 413 (54.3) 147 (51.6) 266 (55.9) 0.249
p-value2 0.015 0.089 0.095
Clinical characteristics
Overall 37.3 (0.96) 37.3 (0.93) 37.3 (1.0) 0.895Mean axillary
PCV9 37.2 (0.80) 37.2 (0.81) 37.3 (0.79) 0.675
temperature4, uC (SD)
Placebo 37.4 (1.1) 37.5 (1.0) 37.4 (1.1) 0.768
p-value2 0.005 0.032 0.05
Overall 222 (27.3) 85 (29.7) 137 (26.0) 0.255Axillary temperature $38uC,
PCV9 89 (23.3) 29 (23.0) 60 (23.4) 0.927
N (%)
Placebo 133 (30.9) 56 (35.0) 77 (28.4) 0.153
p-value2 0.016 0.028 0.193
Overall 1054 (72.6) 369 (71.9) 685 (73.0) 0.654Fever5, N (%)
PCV9 488 (70.2) 155 (67.4) 333 (71.6) 0.252
Placebo 566 (74.9) 214 (75.6) 352 (74.4) 0.713
p-value2 0.047 0.039 0.333
Overall 624 (42.9) 209 (40.7) 415 (44.1) 0.205Vomit6, N (%)
PCV9 275 (39.5) 85 (37.0) 190 (40.8) 0.333
Placebo 349 (46.0) 124 (43.7) 225 (47.4) 0.321
p-value2 0.014 0.124 0.042
Overall 45 (3.1) 9 (1.8) 36 (3.9) 0.029Seizures7, N (%)
PCV9 23 (3.3) 4 (1.7) 19 (4.1) 0.102
Placebo 22 (2.9) 5 (1.8) 17 (3.6) 0.152
p-value2 0.661 0.973 0.685
Overall 165 (11.4) 122 (23.8) 43 (4.6) ,0.001Cyanosis8, N (%)
PCV9 82 (11.8) 59 (25.5) 23 (5.0) ,0.001
Placebo 83 (11.0) 63 (22.3) 20 (4.2) ,0.001
p-value2 0.617 0.397 0.584
Overall 91.3 (5.7) 89.8 (5.5) 92.2 (5.5) ,0.001Mean oxygen saturation % on room air, (SD)
PCV9 91.1 (6.6) 89.0 (5.8) 92.1 (6.8) ,0.001
Placebo 91.6 (4.6) 90.3 (5.2) 92.4 (4.0) ,0.001
p-value2 0.072 0.008 0.395
Overall 358 (24.8) 223 (44.1) 135 (14.4) ,0.001Mean oxygen saturation
PCV9 175 (25.4) 107 (47.8) 68 (14.7) ,0.001
on room air ,90%9, N (%)
Placebo 183 (24.3) 116 (41.1) 67 (14.2) ,0.001
p-value2 0.619 0.135 0.852
Overall 50 (22–130) 54 (24–130) 48 (22–96) ,0.001Median respiratory rate
PCV9 50 (24–130) 58 (24–130) 48 (24–90) ,0.001
breaths per minute10, (range)
Placebo 48 (22–100) 52 (24–100) 48 (22–96) ,0.001
p-value2 0.167 0.040 0.439
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Overall 927 (63.5) 459 (88.8) 468 (49.6) ,0.001Clinical pneumonia, N (%)
PCV9 419 (59.9) 207 (89.2) 212 (45.4) ,0.001
Placebo 508 (66.8) 252 (88.4) 256 (53.8) ,0.001
p-value2 0.007 0.774 0.010
Overall 763 (84.4) 300 (89.3) 463 (81.5) 0.002WHO severe pneumonia , N (%)11
PCV9 352 (81.5) 143 (91.1) 209 (76.0) ,0.001
Placebo 411 (87.1) 157 (87.7) 254 (86.7) 0.749
p-value2 0.021 0.319 0.001
Overall 628 (43.1) 90 (17.4) 538 (57.2) ,0.001Wheezing12, N (%)
PCV9 317 (45.4) 34 (14.7) 283 (60.7) ,0.001
Placebo 311 (40.9) 56 (19.7) 255 (53.7) ,0.001
p-value2 0.083 0.136 0.029
Overall 128 (8.8) 95 (18.4) 33 (3.5) ,0.001Bronchial breathing, N (%)
PCV9 57 (8.2) 41 (17.7) 16 (3.4) ,0.001
Placebo 71 (9.3) 54 (19.0) 17 (3.6) ,0.001
p-value2 0.428 0.710 0.903
Overall 19 (1.3) 3 (0. 59) 16 (1.7) 0.072Mechanical ventilation , N (%)13
PCV9 7 (1.0) 1 (0.43) 6 (1.3) 0.283
Placebo 12 (1.6) 2 (0.72) 10 (2.1) 0.137
p-value2 0.329 0.679 0.334
Overall 342 (26.6) 189 (43.2) 153 (18.1) ,0.001CXR-AC14, N (%)
PCV9 152 (25.0) 84 (42.0) 68 (16.7) ,0.001
Placebo 190 (28.1) 105 (44.1) 85 (19.4) ,0.001
p-value2 0.215 0.656 0.308
Overall 2 (0–49) 4 (0–49) 1 (0–42) ,0.001Median hospital stay in days, (range)
PCV9 2 (0–49) 5 (0–49) 1 (0–24) ,0.001
Placebo 2 (0–49) 3 (0–49) 1 (0–42) ,0.001
p-value2 0.949 0.070 0.378
Overall 101 (6.9) 92 (17.8) 9 (0.95) ,0.001Deaths due to LRTI, N (%)
PCV9 50 (7.2) 46 (19.8) 4 (0.86) ,0.001
Placebo 51 (6.7) 46 (16.1) 5 (1.1) ,0.001
p-value2 0.734 0.276 0.759
Laboratory and other investigations
Overall 15 (1–464) 18 (1–464) 14 (1–446.2) 0.007Median CRP mg/l , (range)15
PCV9 15 (1–446.2) 18 (1–443.1) 13 (1–446.2) 0.077
Placebo 16.9 (1–464) 19 (1–464) 15 (1–363.2) 0.036
p-value2 0.102 0.258 0.244
Overall 313 (30.2) 146 (35.5) 167 (26.8) 0.003CRP $40 mg/l, N (%)
PCV9 137 (27.4) 61 (31.3) 76 (24.9) 0.120
Placebo 176 (32.9) 85 (39.4) 91 (28.5) 0.009
p-value2 0.054 0.088 0.309
Overall 0.26 (0.01–302) 0.47 (0.01–302) 0.17 (0.01–150.1) ,0.001Median PCT ng/ml , (range)16
PCV9 0.23 (0.01–175) 0.4 (0.01–175) 0.14 (0.01–119.9) ,0.001
Placebo 0.29 (0.01–302) 0.57 (0.01–302) 0.19 (0.08–150.1) ,0.001
p-value2 0.138 0.233 0.309
Overall 177 (20.5) 87 (28.1) 90 (16.2) ,0.001PCT $2 ng/ml, N (%)
PCV9 78 (18.6) 38 (25.5) 40 (14.8) 0.007
Respiratory Viruses in Hospitalized Children
PLOS ONE | www.plosone.org 5 February 2014 | Volume 9 | Issue 2 | e86448
2.14; p = 0.002) and CoV-OC43 (aOR 3.67; p,0.001) and a
lower prevalence of hBoV (aOR 0.69; p = 0.043) and WUPyV
(aOR 0.66; p= 0.035); Table 3. Concurrent bacteraemia and
infection with at least one of the newly-tested viruses was more
frequent in HIV-infected (7.7%) compared to HIV-uninfected
children (2.5%, aOR 3.49; p = 0.001). There were no differences
in the frequency of bacteraemia comparing children in whom
newly-tested viruses were detected and those without viral
detection both in HIV-infected (7.7% vs. 8.0%; p= 0.911) and
HIV-uninfected children (2.5% vs. 2.9%; p= 0.713).
Respiratory viruses and clinical manifestations
When compared to LRTI-episodes associated with the identi-
fication of only a single virus the detection of multiple viruses in
HIV-infected children was significantly associated with a higher
frequency of bronchial breathing (aOR 2.11; p = 0.015) and in
HIV-uninfected children with a higher prevalence of cyanosis
(aOR 2.50; p= 0.008) and wheezing (aOR 1.55; p = 0.006);
Table 6. No differences were detected in the severity of LRTI-
episodes with single and multiple viral infections using the RISC
score previously developed.
In both HIV-infected and –uninfected children with bacteria
isolated from blood, there were no significant differences in the
clinical and laboratory characteristics between children in whom
viruses were detected and children without any virus detected. The
same was observed restricting the analysis to Streptococcus pneumoniae
isolation (data not shown).
Discussion
To our knowledge, this study provides the most in-depth
analysis of the prevalence of hRV and some of the newly-
discovered respiratory viruses in HIV-infected children. Our study
identified hRV to be the most frequently detected virus both in
HIV-infected and –uninfected children followed by CoV-OC43 in
HIV-infected and hBoV in HIV-uninfected. Most cases of
hospitalizations associated with single infections overall were
noted for hRV and RSV, the rate of co-infections was high in














Placebo 99 (22.3) 49 (30.4) 50 (17.6) 0.005
p-value2 0.205 0.334 0.363
Overall 13 (1–77.6) 12.5 (2.8–77.6) 13.6 (1–64.7) 0.307Median WCC6109
PCV9 12 (1–37.4) 11 (2.8–29.5) 12.2 (1–37.4) 0.502
cells/ml17, (range)
Placebo 13.6 (3.2–77.6) 13 (3.2–77.6) 14.5 (4.3–64.7) 0.371
p-value2 0.037 0.197 0.083
Overall 62 (4.5) 38 (7.8) 24 (2.7) ,0.001Bacteraemia18, N (%)
PCV9 28 (4.3) 12 (5.5) 16 (3.7) 0.288
Placebo 34 (4.8) 26 (9.8) 8 (1.8) ,0.001
p-value2 0.657 0.077 0.086
In parenthesis percent of number studied, unless otherwise indicated.
1: Chi-square or Fischer test and two-tailed Student t-test or Mann-Whitney test comparing HIV groups.
2: Chi-square or Fischer test and two-tailed Student t-test or Mann-Whitney test comparing 9-valent pneumococcal conjugated vaccine (PCV9) and placebo arms.
3Gender: HIV-infected overall female vs. male: 45.1% vs. 54.9%, p = 0.001; HIV-infected PCV9 female vs. male: 41.0% vs. 59.1%, p,0.001; HIV-infected placebo female vs.
male: 48.4% vs. 51.6%, p = 0.451; HIV-uninfected overall female vs. male: 41.5% vs. 58.5%, p,0.001; HIV-uninfected PCV9 female vs. male: 38.8% vs. 61.2%, p,0.001; HIV-
uninfected placebo female vs. male: 44.1% vs. 55.9%, p,0.001.
4Axillary temperature: 813 patients with available information; HIV-infected 286; HIV-uninfected 527.
5Fever: 1451 patients with available information; HIV-infected 513; HIV-uninfected 938.
6Vomit: 1455 patients with available information; HIV-infected 514; HIV-uninfected 941.
7Seizures: 1447 patients with available information; HIV-infected 511; HIV-uninfected 936.
8Cyanosis: 1454 patients with available information; HIV-infected 513; HIV-uninfected 941.
9Oxygen saturation: 1441 patients with available information; HIV-infected 506; HIV-uninfected 935.
10Respiratory rate: 1446 patients with available information; HIV-infected 515; HIV-uninfected 930.
11World Health Organization (WHO) severe pneumonia definition: 904 patients with available information; HIV-infected 336; HIV-uninfected 568.
12Wheezing: 1458 patients with available information; HIV-infected 517; HIV-uninfected 941.
13Mechanical ventilation: 1439 patients with available information; HIV-infected 509; HIV-uninfected 930. At the time of the study it was current practice not to offer
ventilation to severe AIDS patients.
14Alveolar consolidation on chest x-ray (AC-CXR): 1285 patients with available information; HIV-infected 438; HIV-uninfected 847.
15C-reactive protein (CRP): 1035 patients with available information; HIV-infected 411; HIV-uninfected 624.
16Procalcitonin (PCT): 865 patients with available information; HIV-infected 310; HIV-uninfected 555.
17White cell count (WCC): 209 patients with available information; HIV-infected 95; HIV-uninfected 114.
18Bacteria infections: overall 1367 patients had blood specimens available for culture, 486 HIV-infected and 881 HIV-uninfected. Bacteria isolated from HIV-infected
children included: Streptococcus pneumoniae (n = 16), Escherichia coli (n = 9), Salmonella sp (n = 5), Streptococcus viridans (n = 2), Haemophilus influenzae type b (n = 1),
Pseudomonas aeruginosa (n = 1), Haemophilus parainfluenzae (n = 1), Citrobacter freundii (n = 1), Staphylococcus aureus (n = 1) and other Streptococcus (n = 1). Bacteria
isolated from HIV-uninfected children included: Streptococcus pneumoniae (n = 8), Haemophilus influenzae type b (n = 3), Streptococcus viridans (n = 3), Escherichia coli
(n = 2), Klebsiella sp. (n = 2), Salmonella sp (n = 1), Streptococcus agalactiae (n = 1), Staphylococcus aureus (n = 1), Enterococcus faecalis (n = 1), Micrococcus (n = 1) and
Neisseria meningitidis (n = 1). Further 64 (62.7% of all bacteria isolated) and 107 (81.7% of all bacteria isolated) contaminants were cultured in HIV-infected and -
uninfected children, respectively.
doi:10.1371/journal.pone.0086448.t002
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CoV-229E 4 (0.27) 0 4 (0.42) 0.3042 -












































1: Adjusted odds ratio (aOR) adjusted for age, year of sampling, detection of viruses previously-tested and whether received 9-valent pneumococcal conjugate vaccine
or placebo.
2: p-value not adjusted.
3: Previously-tested by immunofluorescence assay.
4: Previously-tested by nested PCR.
5: Including viruses previously-tested by immunofluorescence assay (RSV, Influenza A, PIV I–III and adenovirus) and nested-PCR (hMPV).
6: All multiple infections included at least one newly-tested virus except in 2 HIV-uninfected children. Viral co-infections with at least one newly-tested virus in HIV-
infected children 118 (22.8%) and in HIV-uninfected children 269 (28.5%).
7: Not adjusted for detection of viruses previously-tested.
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Very few viral aetiology studies have been conducted in Africa:
in a Mozambican study of virus-associated acute respiratory
infections (ARI) in infants with an estimated 3–5% HIV
prevalence, the most frequently detected viruses were hRV
(26%), influenza (15%) and adenovirus (14%) [27]. A recent study
from South Africa on children with ARI requiring medical
attention, 61% (N=383) being HIV-infected or HIV-seropositive,
also reported that hRV was the most frequently detected virus
(33%) followed by RSV (30%), PIV (8%) and hBoV (6%) [21]. In
the South African study hospitalized children with respiratory
disease had higher hRV detection rates compared to healthy
children (36% vs. 19%; p= 0.047) which may indicate a causality
effect of hRV in disease [21]. In Kenya in older children (5–17
years old), despite hRV being the most commonly detected virus
(38%) in patients presenting with ARI, its detection rate was
similar among asymptomatic controls [28]. Indeed two other
studies in Kenya found that with the exception of RSV, viral
detection in the nasopharynx did not have a significant association
with pneumonia in hospitalized children under 5 years [29] or
under 12 years, [30] compared to children both without symptoms
of URTI or with respiratory symptoms but not meeting any
criteria for pneumonia.
It is uncertain as to what the impact of HIV infection on the
duration of shedding of these viruses might be. An analysis of serial
respiratory samples from otherwise healthy children detected
shedding of CoV-NL63 for up 21 days [31], hRV up to 41 days
and of hBoV up to 44 days [32]. Detection of CoV-HKU1 and
CoV-229E in respiratory specimens of transplanted children were
also reported for at least 38 days and 11 weeks, respectively,
possibly suggesting that immunocompromised children may have
a prolonged duration of shedding of these viruses [33,34]. Such
prolonged shedding in immunocompromised individuals such as
HIV-infected children, may result in a greater frequency of co-
incidental identification of these viruses when investigated for
respiratory illness, affect the seasonal occurrence of the viruses as
well as potentially present a threat to greater nosocomial
transmission of these viruses because of higher incidence of
hospitalization of HIV-infected children.
The casual relationship between viral DNA detection, develop-
ment of disease and mixed infections is very complex. In the case
of hBoV serological studies have shown that the presence of viral
DNA in respiratory samples was not proof of an acute primary
infection and that prolonged viral shedding could be an
explanation for viral detection at high rates in asymptomatic
controls [35]. Enrolment of healthy non-hospitalized children and
quantification of viral loads may help to elucidate the problem of
co-infections and is currently being under-taken in a multi-centre
study on aetiology of pneumonia in children [36]. Contradictory
findings on whether infection with multiple viruses contribute to
disease severity in hospitalized children have been reported, with
some studies reporting an increased severity among children with
viral co-infections [21,37] and others finding decrease severity
associated with co-infections [38]. In some studies no differences
were observed [39]. We found that multiple viral infections were
associated with bronchial breathing in HIV-infected children and
with cyanosis and wheezing in HIV-uninfected children. Bacterial
co-infections can also increase the severity of viral diseases [40].
Furthermore, in children with invasive pneumococcal disease,
superimposed viral co-infections are common and may lead to
higher mortality rates [41]. Of the participants in our study from
whom bacterial cultures performed, no differences in clinical and
laboratory characteristics were observed between children with or
without viral infections. Our analysis, however, included PCV9
vaccinees who probably present with less severe LRTI cases since
it was shown before that PCV9 vaccination was associated with a
decrease in LRTI viral-associated hospitalizations [5,23]. We
detected a high prevalence of bacterial co-infections with the
newly-tested viruses especially in HIV-infected children (8%), what
may have contributed to the higher C-reactive protein and
procalcitonin levels, the longer hospital stay and the higher
mortality in HIV-infected children compared to HIV-uninfected.
Our high co-infection detection rates are similar to other
molecular detection studies of paediatric respiratory samples, with
coronaviruses (40–75%) [42,43], hBoV (up to 78%) [13,44,45] and
polyomaviruses (68–79%) [46–48]. Our results may, however,
have under-estimated the true prevalence of viral co-infections
since the previously-studied viruses were tested by immunofluo-
rescence [5] or conventional PCR [23]. Although the sensitivity of
the conventional methods is reported to be high, comparative
studies have shown that RT-PCR is considerably more sensitive
for detection of respiratory viruses [21,49]. Moreover the
specimens tested by immunofluorescence were initially screened
for RSV and only if negative were further tested for influenza A/
B, PIV I–III and adenovirus [5].
Limitations of our study include that this was a post-hoc analysis
and only 70% of specimens collected during the study period were
available for further testing [24]. Compared with the specimens
available for RT-PCR the specimens unavailable were collected
from younger children and were more likely to have tested positive
for a previously-studied virus. This selection bias may have also
contributed to an under-estimation of the number of co-infections.
Along the same line RSV-associated LRTI are more common
among younger children [21,39], for whom we had less available
samples increasing our uncertainty on the prevalence of RSV co-
infections with the newly-tested viruses.
An equal proportion of PCV9- and placebo-recipients hospi-
talized with LRTI were investigated in this study and our analyses
were adjusted for the initial intervention arm. Further detailed
analyses on the effect of PCV9 on the incidence of hospitalization
associated with the individual newly-tested viruses will be reported
on in future.
Although the development of new diagnostic techniques allows
more detailed investigation and has led to the discovery of a
number of new putative respiratory pathogens, the role for some of
these potential pathogens in respiratory illness remains speculative
in the absence of fulfilling Koch’s postulates for causality. In the
present study we demonstrate that at least one respiratory virus
was identified in the majority of HIV-infected and HIV-uninfected
children hospitalized for LRTI. The difficulty in attributing
disease causality to specific viruses due to the high frequency of
viral co-infection suggests a possible synergy among different
pathogens during childhood LRTI.
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